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Abstract
Aims Readmission after hospitalization for acute decompensated heart failure (HF) remains a major public health problem.
Use of remote dielectric sensing (ReDS) to measure lung water volume allows for an objective assessment of volume status
and may guide medical optimization for HF. We hypothesized that the use of ReDS would lower 30 day readmission in patients
referred to rapid follow-up (RFU) clinic after HF discharge.
Methods and results We conducted a retrospective analysis of the use of ReDS for patients scheduled for RFU within 10 days
post-discharge for HF at Mount Sinai Hospital between 1 July 2017 and 31 July 2018. Diuretics were adjusted using a
pre-specified algorithm. The association between use of ReDS and 30 day readmission was evaluated. A total of 220 patients
were included. Mean age was 62.9 ± 14.7 years, and 36.4% were female. ReDS was performed in 80 (36.4%) and led to med-
ication adjustment in 52 (65%). Use of ReDS was associated with a lower rate of 30 day cardiovascular readmission [2.6% vs.
11.8%, hazard ratio (HR): 0.21; 95% confidence interval (CI): 0.05–0.89; P = 0.04] and a trend towards lower all-cause readmis-
sion (6.5% vs. 14.1%, HR: 0.43; 95% CI: 0.16–1.15; P = 0.09) as compared with patients without a ReDS assessment.
Conclusions ReDS-guided HF therapy during RFU after HF hospitalization may be associated with lower risk of 30 day
readmission.
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Introduction
Hospitalization for decompensated heart failure (HF) marks a
turning point in patients’ lives. More than half of hospitalized
HF patients will be re-hospitalized or die within 6 months of
discharge. With an increasing prevalence of HF [regardless
of ejection fraction (EF)], direct costs associated with care
of hospitalized HF patients are projected to cross $70 billion
by 2030.1–4 Accordingly, the Center for Medicare & Medicaid
Services have targeted hospitals with financial penalties for
failing to achieve a 30 day readmission rate in line with na-
tional averages.5
Despite marked advancements in the treatment of HF, re-
ducing HF readmissions remains a challenge. Studies of tele-
medicine, utilizing remote monitoring of daily weights,
blood pressure, heart rate, and symptoms, combined with
nurse health coaching interventions, have yielded inconsis-
tent results with respect to demonstrating improvements in
HF hospitalization and mortality.6–8 Early follow-up appoint-
ments after hospital discharge, however, have been
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associated with lower rates of readmission for HF.9 More re-
cently, remote monitoring of pulmonary arterial pressures
using a fully implantable pressure sensor has been shown to
reduce hospitalizations for patients with HF with preserved
(HFpEF) or reduced EF (HFrEF)10,11; but limited access, reim-
bursement challenges, and the need for additional staffing
have slowed the widespread adoption of this technology.
Use of a novel, non-invasive electromagnetic energy-based
technology to directly measure lung water may be an effec-
tive strategy to lower HF hospitalizations. Remote dielectric
sensing (ReDS; Sensible Medical Innovations, Ltd., Netanya,
Israel) measures the dielectric properties of tissues, which
are mainly determined by the pulmonary fluid content. Use
of this system in a point-of-care (POC) environment can aid
providers in the assessment of a patient’s volume status after
hospital discharge to guide further adjustment of diuretic
therapy. As such, we hypothesized that among patients re-
ferred to a HF nurse practitioner-led clinic within 10 days of
hospital discharge for HF, use of ReDS POC testing would be
associated with a lower rate of 30 day cardiovascular (CV)
and all-cause hospital readmissions as compared with no
ReDS use.
Methods
We conducted a retrospective observational cohort study in-
cluding adult patients (age ≥ 18 years) who presented to a HF
rapid follow-up (RFU) clinic within 10 days of discharge after a
hospitalization for HF between 1 July 2017 and 31 July 2018
at the Mount Sinai Hospital in New York, New York. Patients
with HFpEF and HFrEF were included (Figure 1). Baseline
characteristics, co-morbid conditions, ReDS application, med-
ication changes, 30 day readmission, and cause of readmis-
sion were collected for all patients. The study was approved
by the Institutional Review Board at the Icahn School of Med-
icine at Mount Sinai Hospital.
The RFU clinic is staffed by a specialized HF nurse practi-
tioner with physician oversight. During this visit, HF signs
and symptoms were assessed; guideline-directed medical
therapy (GDMT) was reviewed and optimized; adherence,
lifestyle changes, and education were reinforced. These
changes and interventions were communicated to the pri-
mary care physician or cardiologist.
ReDS testing was considered for all patients as part of rou-
tine care in RFU clinic. ReDS technology has been described
previously.11,12 The system employs low-power electromag-
netic signals emitted into the body to measure the dielectric
properties of tissues. The ReDS™ Wearable System consists of
two sensors in a wearable vest positioned on the front and
back of the patient’s thorax without requiring direct skin con-
tact, allowing measurements to be performed through light
clothing. These signals are emitted through the right
mid-thorax and received posteriorly after passing through tis-
sue. The characteristics of the received signals are affected by
the fluid content of tissue in the path of the signal. The wear-
able vest is connected by a cable to a bedside monitor con-
sole. Measurements are provided after 90 s and recorded in
the patient’s chart. Normal intrathoracic fluid content (be-
tween 20% and 35%) has been validated using different quan-
titative imaging modalities including computed tomography,
nuclear magnetic resonance imaging, and positron emission
tomography.11,12 Readings over 35% represent increased in-
trathoracic fluid content.
All changes to GDMT and diuretic therapy during the RFU
visit were made in accordance with the American College of
Cardiology/American Heart Association/Heart Failure Society
of America (ACC/AHA/HFSA) HF guideline,13 tempered by vi-
tal signs, history, and signs and symptoms of HF. For those
with ReDS readings obtained during clinic visits, GDMT and
diuretic therapy were adjusted based upon a pre-specified al-
gorithm (Table 1).
The two primary endpoints were 30 day CV and all-cause
hospital readmission after index HF hospitalization. Second-
ary endpoints were all-cause death and the combined out-
come of all-cause death or re-hospitalization within 30 days.
Figure 1 CONSORT diagram. HF, heart failure; ReDS, remote dielectric sensing.
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Follow-up time was based on the last point of contact either
via telephone or office appointment.
Baseline characteristics in patients with ReDS vs. without
ReDS assessment were compared using χ2 and Fisher’s exact
tests for categorical variables and Student’s t-tests for contin-
uous measures as appropriate. Event rates were estimated
with the Kaplan–Meier method, and univariate Cox regres-
sion models were used to evaluate the unadjusted associa-
tion between ReDS and 30 day adverse events after the
index hospital discharge. The instantaneous risk of
re-hospitalization within 30 days was computed using
Epanechnikov kernel smoothed hazard function. The inde-
pendent association between use of ReDS and 30 day CV
and all-cause readmission was evaluated with multivariable
Cox regression modelling and reported with adjusted hazard
ratios (HRs) and 95% confidence interval (CIs). All covariates
with a level of significance < 0.20 on univariate analysis were
sequentially included in the multivariable model, and only
those with a level of significance of <0.10 were included in
the final model. A complete list of covariates included in each
multivariable logistic regression model is reported in the ta-
bles. Co-linearity was assessed by the variance inflation fac-
tor, which is an index that measures how much the
variance of an estimated regression coefficient is increased
because of collinearity. The proportionality assumption for
the Cox models was verified using the Schoenfeld residuals
Table 1 Pre-specified algorithm to adjust guideline-directed medical therapy on the basis of the obtained ReDS values during a follow-up
visit
ReDS Reading (value, %) Action
≤20% Hold diuretics
21–35% Maintain current diuretic dosing and optimize guideline-directed medical therapy
36–45% Increase diuretics and return to rapid follow-up in 1 week
≥46% Consider outpatient intravenous loop diuretic or hospitalization
Table 2 Baseline clinical characteristics and medication use on hospital discharge among patients who presented for RFU visit, stratified
by ReDS use vs. no ReDS use
Overall (n = 220) ReDS (n = 80) No ReDS (n = 140) P-value
Clinical characteristics
Age, years 62.9 ± 14.7 65.2 ± 13.2 61.5 ± 15.4 0.08
Male sex 139 (63.2%) 53 (66.3%) 86 (61.4%) 0.48
Body mass index, kg/m2 28.8 ± 7.0 27.3 ± 5.1 29.7 ± 7.7 0.02
White race 46 (20.9%) 17 (21.3%) 29 (20.7%) 0.93
Arterial hypertension 156 (72.2%) 60 (75.0%) 96 (70.6%) 0.49
Diabetes mellitus 90 (41.7%) 33 (41.3%) 57 (41.9%) 0.92
Renal insufficiency 49 (61.3%) 49 (61.3%) 77 (55.0%) 0.37
Chronic obstructive pulmonary disease 77 (35.0%) 28 (35.0%) 49 (35.0%) 1.00
Atrial fibrillation 90 (40.9%) 28 (35.0%) 62 (44.3%) 0.18
Coronary artery disease 112 (52.1%) 44 (55.0%) 68 (50.4%) 0.51
Smoking status 0.38
Never smoker 86 (43.2%) 32 (43.2%) 54 (43.2%)
Current smoker 22 (11.1%) 11 (14.9%) 11 (8.8%)
Former smoker 91 (45.7%) 31 (41.9%) 60 (48.0%)
New York Heart Association class 0.35
I 1 (0.5%) 0 (0.0%) 1 (0.8%)
II 53 (26.1%) 19 (25.7%) 34 (26.4%)
III 126 (62.1%) 50 (67.6%) 76 (58.9%)
IV 23 (11.3%) 5 (6.8%) 18 (14.0%)
Left ventricular ejection fraction < 40% 143 (66.2%) 56 (70.9%) 87 (63.5%) 0.27
Number of prior hospitalizations 2.1 ± 1.9 2.0 ± 1.7 2.2 ± 2.1 0.41
Brain natriuretic peptide, pg/mL 917.2 ± 1083.3 979.4 ± 1300 881.0 ± 937.9 0.52
Medications at hospital discharge
ARNIs 35 (15.9%) 12 (15.0%) 23 (16.4%) 0.78
ACE inhibitors or ARBs 109 (49.6%) 44 (55.0%) 65 (46.4%) 0.22
Mineralocorticoid receptor antagonists 92 (41.8%) 37 (46.3%) 55 (39.3%) 0.31
Beta-blockers 185 (84.1%) 67 (83.8%) 118 (84.3%) 0.92
Calcium channel blockers 17 (7.7%) 9 (11.3%) 8 (5.7%) 0.14
Loop diuretics 190 (86.4%) 69 (86.3%) 121 (86.4%) 0.97
Thiazide diuretics 12 (5.5%) 3 (3.8%) 9 (6.4%) 0.40
Inotropes 14 (6.4%) 2 (2.5%) 12 (8.6%) 0.08
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARNIs, angiotensin receptor-neprilysin inhibitors; ReDS, remote
dielectric sensing.
Results are reported as n (%) or mean ± standard deviations.
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method. Discrimination of the model was quantified with C-
statistic. Two-sided P-values < 0.05 were considered to indi-
cate statistical significance. All statistical analyses were per-
formed with the use of STATA software, version 14.0 (Stata
Corp., College Station, Texas).
Results
Baseline characteristics and remote dielectric
sensing assessments
A total of 220 patients presented to RFU clinics within 10 days
of HF hospitalization. The median time to RFU appointment
after discharge was 6 days [inter-quartile range (IQR), 5 to
8 days]. The mean age was 62.9 ± 14.6 years, and 36.4% were
women. Most patients were hospitalized at least two times in
the preceding year, 65.5% had HFrEF, and 68% were New
York Heart Association (NYHA) Class III and IV (Table 2). A to-
tal of 80 patients (36.4%) had ReDS readings during their visit,
and the median ReDS value was 33 (IQR, 30 to 38). Reasons
ReDS was not performed included body habitus (n = 28;
20%), wearable defibrillator vest (n = 6; 4.3%), presence of
port for infusion of inotropes or other medication (n = 4;
2.9%), and unknown in the remaining 102. Aside from a
higher body mass index in those who did not have a ReDS
reading obtained, there were no significant baseline differ-
ences between patients who had a ReDS reading and those
who did not (Table 2). The rate of HF medication adjustment
was higher in patients who had a ReDS assessment than in
those who did not have a ReDS reading (69.1% vs. 55.7%; uni-
variate odds ratio: 1.77; 95% CI: 1.01–3.12; P = 0.047).
Outcomes
Over a median follow-up time of 211 days (IQR, 123 to
354 days), there were 12 deaths and 44 all-cause hospitaliza-
tions. When restricted to a 30 day post-discharge period,
there were 24 hospitalizations yielding a 30 day all-cause re-
hospitalization rate of 11% (Table 3), the majority of which
were due to CV causes (8.2% for the whole cohort and
18/24 hospitalizations). The majority of CV hospitalizations
were due to HF (n = 12/18, 66.7%). The median time to first
re-hospitalization was 27 days (IQR, 19 to 49 days); the
highest risk for re-hospitalization was observed between 20
and 25 days post-discharge (Figure 2). Among patients who
had a ReDS assessment, median time to re-hospitalization
was 40 compared with 22 days among patients without a
ReDS assessment.
Rates of 30 day adverse events in patients with a ReDS vs.
without ReDS assessment are reported in Table 4 and Figure
3. A ReDS assessment was associated with significantly lower
30 day CV readmissions (2.6% vs. 11.8%; HR: 0.21; 95% CI:
0.05–0.89, P = 0.04) (Figure 4A) with a trend towards lower
rates of 30 day all-cause readmissions (6.5% vs. 14.1%; HR:
0.43; 95% CI: 0.16–1.15, P = 0.09) (Figure 4B). A ReDS assess-
ment was also associated with a significantly lower combined
endpoint of 30 day death or CV readmissions (HR 0.29 95: CI
0.08–0.99, P = 0.047) (Figure 4C), whereas there was a trend
towards an association with lower combined endpoint of
30 day death or all-cause readmissions (HR 0.41; 95% CI
0.15–1.09, P = 0.07) (Figure 4D).
Multivariable logistic regression models for all-cause and
CV readmissions at 30 days are reported in Table 5. The
Table 3 Causes of 30 day hospital readmission (n = 24)
Re-hospitalization for cardiovascular causes 18 (75.0%)
Heart failure-related hospitalization 12/18 (66.7%)
Non-heart failure-related hospitalization 6/18 (33.3%)
Re-hospitalization for non-cardiovascular causes 6 (25.0%)
Figure 2 Daily hazard of any re-hospitalization within 30 days post-hospital discharge.
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covariates associated with 30 day CV readmissions were num-
ber of prior hospitalizations, male sex, atrial fibrillation, and
use of ReDS. The only factor associated with of 30 day
all-cause readmissions after adjustment was the number of
prior hospitalizations.
Discussion
In this retrospective single-centre study, we explored the im-
pact of performing ReDS assessments after HF hospitalization
on 30 day outcomes. The findings of our analysis are as fol-
lows: (i) among patients who presented to an RFU clinic after
admission for HF, the rate of all-cause 30 day
re-hospitalization was approximately 11%, and (ii) the use of
ReDS technology during a RFU clinic visit was associated with
lower risk of 30 day CV re-hospitalization and a trend towards
lower risk of 30 day all-cause re-hospitalization as compared
with those of patients in whom ReDS was not utilized.
Reducing readmissions for HF is a major public health fo-
cus. Early follow-up post-discharge for HF has been shown
to improve outcomes for patients admitted with HF9 and is
recommended by the ACC/AHA/HFSA guidelines for the
management of HF.13 Accordingly, in our cohort of patients,
the RFU visit within 10 days of discharge alone was associated
with lower rates of 30 day readmission compared with the
national average of approximately 19% noted in a previous
Get With the Guidelines Registry analysis. Our cohort in-
cluded a high-risk HF population with over two-thirds describ-
ing NYHA Class III to IV symptoms.
Congestion is the main cause for HF decompensation and
hospitalization, manifested as dyspnoea, orthodema, and/or
bendopnea.6,14,15 Inadequate decongestion during hospitali-
zation for HF and recurrent congestion post-discharge are
postulated to partially explain the high rates of hospital
readmission.10,14,16 Yet detecting congestion by physical
exam and laboratory markers in the absence of symptoms
can be challenging and is subject to limitations.17 Specifically,
signs, symptoms, and weight changes can be poor surrogates
for filling pressures and therefore unreliable predictors of HF
readmission.18 As such, the use of ReDS wearable vest as a
simple non-invasive tool to guide optimization of volume sta-
tus presents considerable appeal.
This retrospective analysis of over 200 racially diverse pa-
tients in a vulnerable post HF hospitalization discharge period
reveals that the use of ReDS technology is safe and may be
associated with lower risk of 30 day readmissions. A thoracic
Table 4 Rates of death and re-hospitalization at 30 days after hospital discharge
ReDS (n = 80) No ReDS (n = 139) ARD (%) Hazard ratio (95% CI) P-value
All-cause death 1.3% (1) 1.5% (2) 0.2 0.86 (0.08–9.50) 0.90
All-cause re-hospitalization 6.5% (5) 14.0% (19) 7.5 0.43 (0.16–1.16) 0.09
Cardiovascular re-hospitalization 2.6% (2) 11.8% (16) 9.2 0.21 (0.05–0.90) 0.04
All-cause death or re-hospitalization 6.5% (5) 14.7% (20) 8.2 0.41 (0.15–1.09) 0.08
All-cause death or cardiovascular re-hospitalization 3.9% (3) 12.5% (17) 8.6 0.29 (0.09–0.99) 0.049
ARD, absolute risk difference; CI, confidence interval; RFU, rapid follow-up; ReDS, remote dielectric sensing.
Results are reported as Kaplan–Meier estimates (number of events).
Figure 3 Impact of rapid follow-up clinic with ReDS-guided management on 30 day readmission rates. ReDS, remote dielectric sensing; RFU, rapid fol-
low-up.
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fluid content reading was provided to the nurse practitioner,
allowing for optimization of volume status using a
pre-specified algorithm to adjust diuretics. The use of this
non-invasive POC approach in an outpatient setting was asso-
ciated with lower 30 day readmissions compared with pa-
tients without ReDS assessments. We hypothesize that this
benefit may be mediated by the increased number of medica-
tion changes made in the patients for whom ReDS assess-
ments were performed. The use of a standardized algorithm
to optimize volume status and inhibitors of the renin–angio-
tensin–aldosterone system may have contributed to the ob-
served statistically significant reduction in CV readmissions.
Although not formally captured, our anecdotal experience
suggested that the ReDS measurement seemed to create a
‘teachable moment’ to review medications, compliance, and
dietary restrictions. Further study is needed to reveal
whether use of ReDS in this setting improves adherence
and subsequent follow-up.
Figure 4 Rates of death and re-hospitalization within 30 days in patients with vs. without ReDS during the rapid follow-up visit. (A) Any re-hospital-
ization. (B) Cardiovascular re-hospitalization. (C) Death or any re-hospitalization. (D) Death or cardiovascular re-hospitalization. ReDS, remote dielectric
sensing.
Table 5 Predictors of 30 day cardiovascular and all-cause re-hospi-






ReDS 0.17 (0.03–0.87) 0.03
Male sex 6.87 (1.53–30.91) 0.01
Atrial fibrillation 2.76 (1.02–7.47) 0.05
Number of prior hospitalizationsa 1.31 (1.12–1.53) 0.001




ReDS 0.47 (0.17–1.27) 0.14
Male sex 2.30 (0.90–5.89) 0.08
Atrial fibrillation 2.17 (0.96–4.91) 0.06
Number of prior hospitalizationsa 1.24 (1.08–1.41) 0.002
HR, hazard ratio; ReDS, remote dielectric sensing.
C-statistics for the cardiovascular re-hospitalization model: 0.82.
aPer number of prior hospitalization increase; C-statistics for the
all-cause re-hospitalization model: 0.69.
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There are several limitations that warrant discussion. First,
owing to the retrospective, single-centre design of this study,
our findings have to be considered hypothesis generating.
Second, the small sample size precluded a
non-parsimonious multivariable adjustment of our predictive
models; therefore, our effect estimates are potentially sub-
ject to significant confounding bias, and, importantly, we
could not perform an analysis in sub-groups of clinical inter-
est such as HFrEF vs. HFpEF. Third, not all patients hospital-
ized for HF at Mount Sinai Hospital may have been
identified for RFU clinic, raising the possibility of selection
bias. Further, among those presenting for RFU clinic, ReDS
readings were performed in less than 40% of patients, and
there was no pre-defined protocol as to which patients
underwent ReDS readings. Reasons as to why ReDS readings
were not performed were often not listed in the chart, which
may have also introduced bias. Despite these limitations, the
fact that patients who had ReDS assessments performed
were similar to those who did not have ReDS assessments
performed is reassuring. We did not capture readmissions
to other hospitals; however, the Mount Sinai Health system
is large and far reaching in this geographic location with mul-
tiple hospitals.
Conclusions
Early readmission after hospitalization for HF remains a major
clinical challenge. Use of POC testing with ReDS technology
after hospital discharge for HF allowed optimization of medi-
cations and appeared to be associated with lower risk of
30 day CV readmissions in a high-risk cohort. Further experi-
ence with POC ReDS testing may provide insights into the fre-
quency of congestion early after HF discharge, reduction in
hospital readmission, and optimization of diuretic therapy
and GDMT. Our preliminary findings warrant evaluation in a
randomized controlled trial to evaluate the clinical impact of
using ReDS technology after HF hospitalizations to reduce
early readmissions.
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